1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Regulation

UK Blocks 82 From Parallel Export

BGMA Does Not Foresee Imminent Shortages Amid Coronavirus

 
• By Dave Wallace

The UK government has added 82 items to its list of medicines that cannot be parallel exported from the country, including amoxicillin, insulin, paracetamol and several common proton pump inhibitors. The move comes as local off-patent industry association the BGMA has insisted that no short-term or medium-term shortages are foreseen amid the coronavirus pandemic.

Red_82
The UK has added 82 items to its list of items blocked from parallel export • Source: Shutterstock

The UK government has added 82 items to its list of medicines that cannot be parallel exported from the country. Among the items that cannot be parallel exported from the UK as of 21 March are amoxicillin, paracetamol and insulin, as well as enoxaparin, heparin, hydrocortisone, morphine, ondansetron and proton pump inhibitors such as lansoprazole, omeprazole, and pantoprazole.

According to the latest figures from market researcher WaveData, omeprazole, lansoprazole and paracetamol were among the molecules with the most...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Regulatory Recap: FDA Starts ‘Radical Transparency’ Era After Publishing Over 200 CRLs

 
• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.

Bio-Thera Matches Alvotech With US Golimumab Filing Acceptance

 
• By Dean Rudge

Bio-Thera is one step closer to launching a biosimilar to Johnson & Johnson’s Simponi in the US, following FDA acceptance of its BAT2506 proposed golimumab candidate.

‘Our Position Has Naturally Shifted’ – How Standalone Sandoz Is Taking On Originator Abuses

 
• By Dave Wallace

As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.

ANDA User Fees: Complex Generics, Transparency, Communications Are Early Negotiation Targets

 
• By Sue Sutter

Teva seeks a dedicated development program and first-cycle approval metrics for complex generics. Role of artificial intelligence in the generic drug review process is a talking point for both agency and industry at reauthorization kickoff meeting.

More from Policy & Regulation